Peer Exchange

Access to Therapeutic Combinations in Type 2 Diabetes
September 12, 2017 – 
Mark Warren, MD, explains some of the benefits associated with the GLP-1 receptor agonist/insulin combinations and the importance of formulary access to these newer agents.
Hypoglycemia: An Unrecognized Complication in Diabetes
September 05, 2017 – 
Mark Warren, MD, discusses the lack of accurate data on the rates of hypoglycemia in the outpatient setting among patients with diabetes.
Clinical Evidence of Insulin Degludec in Type 2 Diabetes
September 05, 2017 – 
Mark Warren, MD, reviews the clinical trial evidence with insulin degludec in type 2 diabetes, highlighting the recent DEVOTE trial and what it adds to the SWITCH study findings.
Diabetes: Shifting the Mindset for Cardiovascular Benefits
August 30, 2017 – 
John Anderson, MD, reviews data from the EMPA-REG OUTCOME trial with empagliflozin and discusses the impact the findings had on the diabetes field.
Complexities in Diabetes Care in 2017
August 30, 2017 – 
John Anderson, MD, discusses the complexities involved in the management of diabetes and highlights the key factors to consider.
Formulary Access to Insulins in Type 2 Diabetes
August 29, 2017 – 
Mark Warren, MD, emphasizes the importance of formulary access to the insulin therapies prescribed and the role of biosimilar insulins in type 2 diabetes.
Deciding Among Insulin Therapies for Type 2 Diabetes
August 29, 2017 – 
Mark Warren, MD, explains some of the key benefits associated with the ultra–long acting insulins and shares his clinical rationale for switching therapies in type 2 diabetes.
Practical Decisions in Type 2 Diabetes
August 22, 2017 – 
Mark Warren, MD, shares how he makes type 2 diabetes treatment decisions and explains the link between regimen complexity, compliance, and resource utilization.
Barriers to Insulin Therapy in Type 2 Diabetes
August 22, 2017 – 
Mark Warren, MD, provides an overview of some of the key barriers to initiating insulin therapy in patients with type 2 diabetes.
Role of GLP-1/Insulin Combinations
August 15, 2017 – 
Louis S. Christos, RPh, offers a payer perspective regarding the role of glucagon-like peptide-1 receptor agonist/insulin combinations and discusses the importance of real world evidence.
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome to the new and improved AJMC.com, the premier managed markets network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!